Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase - 24/11/24

Doi : 10.1016/j.therap.2024.05.003

Olivier Maillard ^a,^b,^c,^{^{1
French research network supported by Inserm and French Clinical Research Infrastructure Network (F-CRIN) – home.html.},}^⁎ , René Bun ^a,^b,^c, Moussa Laanani ^a,^d, Amandine Verga-Gérard ^a,^e, Taylor Leroy ^a,^e, Nathalie Gault ^a,^f, Candice Estellat ^a,^g, Pernelle Noize ^a,^h, Florentia Kaguelidou ^a,^i,^j, Agnès Sommet ^a,^k, Maryse Lapeyre-Mestre ^a,^k, Annie Fourrier-Réglat ^a,^h, Alain Weill ^a,^l,^{^{2
These authors contributed equally.}}, Catherine Quantin ^a,^m,^n,^{^{2
These authors contributed equally.}}, Florence Tubach ^a,^g,^{^{2
These authors contributed equally.}}
^a Réseau de recherche en épidémiologie clinique et en santé publique/French Clinical Research Infrastructure Network (RECaP F-CRIN) Inserm network, 54500 Vandoeuvre-lès-Nancy, France
^b Department of Public Health and Research, CHU de La Réunion, 97400 Saint-Pierre, Ile de La Reunion, France
^c Clinical Investigation Center, INSERM CIC 1410, CHU de La Réunion, 97400 Saint-Pierre, Ile de La Reunion, France
^d French National Health Insurance, 75000 Paris, France
^e INSERM, CIC-EC 1433, 54100 Nancy, France
^f INSERM, CIC-EC 1425, hôpital Bichat, 75018 Paris, France
^g Sorbonne Université, INSERM, institut Pierre-Louis d’épidémiologie et de Santé publique, AP–HP, hôpital Pitié-Salpêtrière, département de Santé publique, centre de pharmacoépidémiologie (Cephepi), CIC-1901, 75000 Paris, France
^h Université de Bordeaux, INSERM, BPH, U1219, Team AHeaD, CHU de Bordeaux, pôle de santé publique, service de pharmacologie médicale, 33000 Bordeaux, France
ⁱ INSERM, CIC-EC 1426, Department of Pediatric Pharmacology and Pharmacogenetics, Clinical Investigations Center, hôpital Robert-Debré, 75019 Paris, France
^j UMR-1123, ECEVE, université Paris Diderot, Sorbonne Paris Cité, 75013 Paris, France
^k Service de pharmacologie médicale et clinique, faculté de médecine, CIC 1436, CHU, université de Toulouse, 31000 Toulouse, France
^l Epiphare (French National Medicines Agency ANSM and French National Health Insurance CNAM), 93200 Saint-Denis, France
^m Service de biostatistiques et d’information médicale (DIM), CHU Dijon Bourgogne, INSERM, université de Bourgogne, CIC 1432, module épidémiologie clinique, 21000 Dijon, France
ⁿ Université Paris-Saclay, UVSQ, Inserm, CESP, 94807 Villejuif, France

^⁎Corresponding author. INSERM CIC 1410, centre hospitalier universitaire de La Réunion, BP 350, 97448 Saint-Pierre cedex, Ile de La Reunion, FranceINSERM CIC 1410, centre hospitalier universitaire de La RéunionBP 350Saint-Pierre cedex97448Reunion

Summary

Aim of the study

The French National Health Data System (SNDS) comprises healthcare data that cover 99% of the population (over 67 million individuals) in France. The aim of this study was to present an overview of published pharmacoepidemiological studies using the SNDS in its maturation phase.

Methods

We conducted a systematic literature review of original research articles in the Pubmed and EMBASE databases from January 2012 until August 2018.

Results

A total of 316 full-text articles were included, with an annual increase over the study period. Only 16 records were excluded after screening because they did not involve the SNDS but other French healthcare databases. The study design was clearly reported in only 66% of studies of which 57% were retrospective cohorts and 22% cross-sectional studies. The reported study objectives were drug utilization (65%), safety (22%) and effectiveness (9%). Almost all ATC groups were studied but the most frequent ones concerned the nervous system in 149 studies (49%), cardiovascular system drugs in 104 studies (34%) and anti-infectives for systemic use in 50 studies (16%).

Conclusion

The SNDS is of growing interest for studies on drug use and safety, which could be conducted more in specific populations, including children, pregnant women and the elderly, as these populations are often not included in clinical trials.

Le texte complet de cet article est disponible en PDF.

Keywords : Pharmacoepidemiology, Healthcare databases, Real world data, Systematic review

Plan

Systematic review registration

Support

Funding statement

Data availability statement

Ethics approval statement

Patient consent statement

Authors’ contributions

Disclosure of interest

Export

Vol 79 - N° 6

P. 659-669 - novembre 2024 Retour au numéro

Article précédent

Isotonitazene, a synthetic opioid from an emerging family: The nitazenes
Jean-Joseph Bendjilali-Sabiani, Céline Eiden, Margot Lestienne, Sabrina Cherki, David Gautre, Thomas Van den Broek, Olivier Mathieu, Hélène Peyrière

| Article suivant

Tramadol intoxication in children: An emerging issue
Guillaume Drevin, Nicolas Picard, Antoine Baudriller, Maria Pena-Martin, Séverine Ferec, Laurent Leuger, Marie Briet, Chadi Abbara

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase - 24/11/24

Summary

Aim of the study

Methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL